LATEST UPDATES » Big Data, Bigger Disease Management and Current preparations to manage the Future Health of Singaporeans       » Big Data in Clinical Research Sector       » Professor Yuk-ling Yung receives Gerard P. Kuiper Prize       » AXA Assistance on Regenerative Medicine       » Singtel – Singapore Cancer Society Race against Cancer 2015       » Jardiance® is the only diabetes medication to show a significant reduction in both cardiovascular risk and cardiovascular death      
Immunovaccine's DPX-Survivac produces sustained, dose related immune responses in Phase I ovarian cancer study
Immunovaccine Inc. a clinical stage vaccine company reported positive results from a Phase I clinical study of the company's cancer vaccine, DPX-Survivac, for the treatment of ovarian cancer. DPX-Survivac consists of survivin-based peptide antigens formulated in the DepoVax™ adjuvanting platform. Survivin has been recognized by the National Cancer Institute (NCI) as a promising tumor-associated antigen (TAA) because of its therapeutic potential and its cancer specificity. Survivin is broadly over-expressed in multiple cancer types in addition to ovarian cancer, including breast, colon and lung cancers. Survivin plays an essential role in antagonizing apoptosis, supporting tumor-associated angiogenesis, and promoting resistance to various anti-cancer therapies. Survivin is also a prognostic factor for many cancers and it is found in a higher percentage of tumors than other TAA's.

The DPX-Survivac vaccine is thought to work by eliciting a cytotoxic T-cell immune response against cells presenting survivin peptides on HLA class I molecules. This targeted therapy attempts to use the immune system to actively and specifically search for and destroy tumor cells. Survivin-specific T-cells have been shown to target and kill survivin-expressing cancer cells while sparing normal cells.

The analysis, which now includes all patients enrolled in the study, confirmed previously reported results and uncovered new findings. All patients receiving the DPX-Survivac combination therapy who were evaluable by tetramer staining (n=10) produced survivin-specific CD8 T cells following one or two vaccinations. Importantly, the CD8 responses were maintained with booster vaccinations. The activation and maintenance of these specific immune cells is of particular interest in immunotherapy since CD8 T cells are implicated in identifying cancer cells, infiltrating tumors and killing cancer targets.

All patients receiving the DPX-Survivac combination therapy (n=12) demonstrated antigen specific immune responses as measured by at least one of the study's three immune monitoring assays (ELISpot, tetramer analysis and multiparametric intracellular cell staining). In 11 of 12 patients, the immune responses were confirmed by two assays (five patients) or three assays (six patients) performed. These immune responses were established with one or two vaccinations and further increased or maintained with follow-up booster vaccinations.

Analysis of immune responses by ELISpot showed that a cohort of patients receiving the higher dose of the vaccine therapy produced an average stimulation factor of greater than 600 times over baseline following their third vaccination. For one of these patients, the stimulation factor reached greater than 1,200 times over baseline.

These immune responses are in agreement with the previously reported average increase of 350 times over baseline for these same patients following their second vaccination.

DPX-Survivac was deemed well tolerated with no significant systemic adverse events reported in any patients recruited in this study. Reported adverse events were restricted to injection site reactions, which were experienced by the majority of patients after repeated vaccinations. Those patients presenting the strongest immune responses were more likely to exhibit more pronounced injection site reactions. There were no dose limiting toxicities experienced during the trial and no patient withdrew consent due to adverse events.

"Our clinical trial data has identified a treatment cohort that consistently produces strong CD8 T cell responses that are clearly detected in the circulation of vaccinated patients," said Marc Mansour, Chief Science Officer of Immunovaccine. "The fact that DPX-Survivac is able to generate and maintain the desired tumor killing T cells provides strong fundamentals for advancing the clinical development of this novel vaccine."

The Phase I DPX-Survivac trial was a multi-center, open-label, dose-ranging study in previously diagnosed ovarian cancer patients who had been treated by surgery and chemotherapy. Under the study protocol, these patients each received a total of three DPX-Survivac vaccinations three weeks apart with a total of 18 ovarian cancer patients completing all three vaccinations. A lead-in cohort of three patients received DPX-Survivac alone to confirm the safety of the vaccine as a monotherapy. Two additional cohorts of six patients each received a low dose or a high dose of DPX-Survivac in combination with a low dose of cyclophosphamide. The trial's primary objective was to evaluate the safety of the vaccine and in combination with cyclophosphamide. A secondary endpoint was the evaluation of the immune response produced by the vaccine therapy.

The Phase I study is part of a Phase I/II trial cleared by the U.S. FDA and Health Canada. The Phase II portion of the trial will be a randomized, double-blinded, placebo-controlled study with a vaccine dose selected based on the Phase I results. The Phase II trial will assess the clinical benefit of DPX-Survivac in patients with advanced ovarian cancer.

The positive results in the company's cancer vaccine program follow immediately on the heels of the company's announcement of similarly strong results from its infectious disease program. Previously, Immunovaccine announced that data from an immunogenicity study of anthrax vaccines formulated in the company's DepoVax™ adjuvanting platform showed DepoVax-based vaccines provided a more rapid and long lasting immune response as compared to the licensed anthrax vaccine BioThrax™. The two studies both leveraged the same DepoVax platform to enhance immune response sharply in different vaccines targeting different indications.

"We're encouraged that the data continues to accumulate showing IMV's technology can speed up immune responses and make them stronger and longer lasting, for a wide range of vaccines," said John Trizzino, chief executive officer of Immunovaccine. "Whether in cancer immunotherapy or in protection against infectious disease, the results are very positive."

Click here for the complete issue.

news A Heroic Voyage — Sydney Brenner's Life in Science
news VeloX, A Minimally Invasive Prosthetic Heart Valve for treating Mitral Regurgitation
news Anti-CD25 monoclonal antibody (90Y-daclizumab) a favorable target towards systemic radio-immunotherapy in Hodgkin's Lymphoma

Credits to Sony Computer Entertainment and click here for behind the scenes.

APBN Editorial Calendar 2015
Trends and Predictions for 2015 Robotics in Healthcare Nutrition Universal Health Coverage
Start-Up Biotech Companies Preventative and Translational Medicine Biofuels ASEAN Economic Community and Asia's Life Sciences Industry
Big Data: Healthcare and Drug Development Antibody Engineering in Japan Christmas Edition
APBN Editorial Calendar 2016
Korea's Biotechnology Industry Nutrition and Allergies: Are we, Too Clean? Medical Devices and Technology: Innovation that leaves an Inspiration Tobacco Smoking: The 'Real' Cost of One Cigarette
Life-Saving Opportunities: A Guide to Regenerative Medicine Occupational Health Water Technology Olympics: Evolution of Sports
Respiratory: Seasonal flu viruses
About Us
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» Editorial Enquiries: biotech_edit@wspc.com
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   Ms PoPo Kwok or Ms Sok Ching Lim
Copyright© 2015 World Scientific Publishing Co Pte Ltd  •  Privacy Policy